Moderna's stock doubles after promising mRNA cancer vaccine results

Moderna's stock price doubled after the company released promising results for its mRNA-based cancer vaccine candidate. The therapy pairs personalised mRNA treatment with the cancer drug Keytruda. Investors responded enthusiastically to the trial data, sending shares sharply higher.